Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy  by Sun, Mei Zhen et al.
Comparison of add-on valproate and primidone in carbamazepine-unresponsive
patients with partial epilepsy
Mei Zhen Sun a, Charles L.P. Deckers b,*, Yu Xi Liu a, Wei Wang c
aDepartment of Neurology, The First Hospital of Shanxi Medical University, Taiyuan, China
b SEIN, Zwolle, The Netherlands
cDepartment of Neurology and Psychiatry, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China
Seizure 18 (2009) 90–93
A R T I C L E I N F O
Article history:
Received 24 April 2008
Received in revised form 11 June 2008
Accepted 20 June 2008
Keywords:
Carbamazepine
Valproate
Primidone
Combination
Partial epilepsy
A B S T R A C T
Purpose: Evaluation of the efﬁcacy of add-on valproate (VPA) or primidone (PRM) in patients with partial
epilepsy unresponsive to carbamazepine (CBZ).
Methods: The trial was prospective and open. Patients, aged 8–58 years, with partial epilepsywho did not
become seizure free on CBZ were randomized to either VPA add-on or PRM add-on. The baseline period
and the evaluation periodwere both 3months. Proportions of patientswith different degrees of reduction
in seizure frequency were determined.
Results: Signiﬁcantly more patients on VPA (51% of 68 patients) achieved a greater than 50% seizure
reduction than on PRM (34% of 68 patients). There was no signiﬁcant difference in percentage seizure free
(26% and 16%, respectively) or in percentage treatment withdrawals due to adverse effects.
Conclusion: Our results indicated that the efﬁcacy of the CBZ/VPA combination tends to be greater than
the efﬁcacy of the CBZ/PRM combination.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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For newly diagnosed epileptic patients, monotherapy with an
antiepileptic drug is the treatment of choice. If the ﬁrst drug fails,
many patients are switched to another drug in monotherapy.
However, one-third of patients does not attain seizure freedom
with monotherapy.1 In order to achieve better seizure control,
these patients are often given combinations of antiepileptic drugs
(also called polytherapy). In a reviewonAED combination therapy
studies in animalmodels and in patients, Deckers et al. identiﬁed a
number of combinations that have increased effectiveness
compared to their individual constituents and/or to other
combinations.2 Higher effectiveness may be attained not only
through higher efﬁcacy, but also through better tolerability. The
combination of carbamazepine and valproate is one of these
combinationswith higher effectiveness. In China, these two drugs
are relatively expensive. Phenobarbital (PB) and primidone (PRM)
are drugs of choice. Primidone is a desoxyphenobarbitalwhichhas* Corresponding author at: SEIN, Dr. Denekampweg 20, 8025 BV Zwolle, The
Netherlands. Tel.: +31 38 4557195; fax: +31 38 4557170.
E-mail addresses: meizhensun23@yahoo.com (M.Z. Sun), clp.deckers@planet.nl
(Charles L.P. Deckers), liuyuxi@163.com (Y.X. Liu), wwang@tjh.tjmu.edu.cn
(W. Wang).
1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.06.009PB as its active metabolite. In animal studies, the anticonvulsant
activity of PRM almost equalled that of PB as chronic treatment of
kindled rats, while PRM was tolerated better.3
Few studies have been performed that have evaluated the
effects of the combination of carbamazepine and primidone. The
aim of the present study is compare both efﬁcacy and tolerability of
add-on valproate and add-on primidone in carbamazepine-
unresponsive patients with partial epilepsy.
2. Methods
2.1. Patients
The trial was initiated in February 2002 and was completed in
October 2004. The inclusion criteria were: age 8 years and older;
diagnosis of partial epilepsy, based on an accurate history and
adequate neurophysiologic data; well-deﬁned types of seizures
according to the International Classiﬁcation of Epileptic Sei-
zures4; patients not becoming seizure free on CBZ as their ﬁrst
antiepileptic drugwith a seizure frequency of at least two seizures
per month during the retrospective baseline period of 3 months.
Criteria for exclusion were not satisfying the inclusion criteria;
inability to give informed consent (e.g. language barrier); absence
and/or myoclonic seizures; acute or progressive neurological
disorders; alcohol or other substance abuse; psychiatric disease;vier Ltd. All rights reserved.
Table 1
Characteristics of patients in the two treatment groups
Group VPA group PRM group
Gender (male:female) 44:24 45:23
Average age (in years) 22.3 (8–58) 22.9 (8–50)
Monthly seizure frequency 6.2 (2–60) 6.8 (2–45)
Fig. 1. Flow diagram of the progress of the trial.
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years of age were asked for informed consent. The protocol of the
study was approved by the ethics committee of the First Hospital
of Shanxi Medical University.
2.2. Procedure
Neurologists of two hospitals of the Shanxi Medical University
identiﬁed eligible patients. After enrolment, patients were
randomized to either VPA add-on or PRM add-on. The dose of
the add-on drugs were titrated in three steps with weekly
intervals. The dose of VPA and PRM were escalated in a stepwise
fashion (200 mg/day, 400 mg/day and 600 mg/day for VPA;
250 mg/day, 500 mg/day, 750 mg/day for PRM). The doses were
not increased further when patients were seizure free or
experienced adverse effects. After the titration period (of ﬂexible
length), the dosages were held stable during a 3-month
maintenance period. The procedures followed were in accor-
dance with the ethical standards of the medical ethical
committees of the hospitals involved and with the Helsinki
Declaration of 1975.
The following outcomemeasures were used: seizure frequency
(for which patients were given diaries) and adverse effects. Serum
levels were collected at the ﬁrst control visit and when doses were
changed. Serum level samples were taken before ingestion of the
morning dose after patients had used a stable dose for 1–2 weeks.
Samples were analyzed by the laboratory of the Shanxi Medical
University with high-pressure liquid chromatography. The
observed serum level of three drugs are in therapeutic level (4–
10 mg/L for CBZ, 50–100 mg/L for VPA, and 20–40 mg/L for
phenobarbital, the main metabolite of PRM).
2.3. Statistics
Sample size calculation was based on the proportion of
patients seizure free. With 61 patients in each treatment group,
the study had a power of 80% and a signiﬁcance level of 0.05 to
show a difference of 25% in patients becoming seizure free. The
number of patients completing maintenance phase, reaching
seizure freedom or a signiﬁcant seizure reductionwere compared
using risk difference and using relative risks with 95% conﬁdence
intervals. Seizure frequencies were compared with the baseline
seizure frequencies and CBZ serum levels were compared with
the baseline serum levels using nonparametric tests (Wilcoxon
signed-rank).
3. Results
3.1. Patients
One hundred and thirty-six (136) patients were enrolled in the
study, and all of these patients were randomized. Sixty-eight
patients were randomized to receive add-on valproate, and 68 to
receive add-on primidone. The characteristics of the patients in the
two groups are shown in Table 1.Table 2
Monthly seizure frequency in different treatment groups
VPA group
N Baseline Add-on P
CPS 33 15.9 (S.D. 6.1) 7.3 (S.D. 2.6) <0.05
SGTCS 21 3.9 (S.D. 0.6) 1.4 (S.D. 0.4) <0.05
SPS 14 18.9 (S.D. 6.0) 7.0 (S.D. 2.8) <0.05
CPS: complex partial seizure; SGTCS: secondarily generalized tonic clonic seizure; SPS:3.2. Effectiveness
In the add-on valproate group, 63 of 68 patients completed the
maintenance period, whereas 57 patients completed the main-
tenance period in the PRM group (Fig. 1). This difference almost
reached statistical signiﬁcance (chi square test: P = 0.07). Themost
common reason for withdrawal in both groups was adverse events
(Fig. 1).
3.3. Efﬁcacy
In both treatment groups, seizure frequencies were reduced
signiﬁcantly from CBZ monotherapy for all seizure types (Table 2).
When comparing the effects of the add-on drugs on an ‘‘intention
to treat’’ basis, there was a trend favouring the VPA group in ‘‘risk’’
of becoming seizure free and signiﬁcantlymore patients in the VPA
group experienced a greater than 50% seizure reduction compared
to the PRM group (Table 3). Similar results are obtained by a ‘‘per
protocol’’ analysis.
3.4. Adverse effects
One patient withdrew from the VPA group due to dizziness and
three due to gastrointestinal complaints (nausea). In the PRM
group, three patients withdrew from the trial due to dizziness,PRM group
N Baseline Add-on P
31 4.5 (S.D. 0.5) 3.6 (S.D. 0.6) <0.05
14 4.3 (S.D. 0.4) 2.5 (S.D. 0.7) <0.05
23 12.8 (S.D. 2.9) 7.2 (S.D. 2.1) <0.05
simple partial seizure; S.D.: standard deviation.
Table 3
Comparison of efﬁcacy in two add-on groups
Seizure reduction (%) VPA group (%) (N = 68) PRM group (%) (N = 68) Risk difference (%) Relative risk (95% CI)
100 26 (18 pts) 16 (11 pts) 10 1.64 (0.84–3.20)
>50 51 (35 pts)a 34 (23 pts)a 17 1.52 (1.01–2.28)
Percentages of patients in different outcome groups are given (with number of patients in parentheses); superscript letter (a): signiﬁcant difference between treatment
groups; 95% CI: 95% conﬁdence interval.
Table 4
Average dosages and serum levels in two add-on groups
Group CBZ dose (mg/day) CBZ monotherapy serum level (mg/L) CBZ polytherapy serum level (mg/L) Add-on dose (mg/day) Add-on serum level (mg/L)
VPA 573 (S.D. 179) 7.7 (S.D. 1.4) 6.4 (S.D. 1.6)a 583 (S.D. 196) 47.6 (S.D. 17.6)
PRM 648 (S.D. 150) 7.8 (S.D. 2.3) 5.9 (S.D. 1.9)a 596 (S.D. 260) 12.2b (S.D. 5.6)
S.D.: standard deviation; superscript letter (a): compared with CBZ in monotherapy, P < 0.05; and superscript letter (b): phenobarbital level.
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gastrointestinal complaints. This treatment difference did not
reach statistical signiﬁcance (risk difference 6% and relative risk
0.43 with 95% conﬁdence interval 0.12–1.59). Adverse effects
in other patients were mild and disappeared while patients
continued to use the drugs.
3.5. Dosages/serum levels
The average dosages used in this study were 583 mg/day for
VPA and 596 mg/day for PRM (Table 4). The maximal dosages used
in maintenance period were 1500 mg/day for PRM and 1600 mg/
day for VPA. The plasma concentrations of CBZ in monotherapy
were signiﬁcantly higher than the CBZ levels in the two treatment
groups (Table 4).
4. Discussion
Our results indicate a trend towards better efﬁcacy in the add-
on valproate group, compared to the add-on primidone group in
carbamazepine-unresponsive patients with partial epilepsy. In our
study, 51.4% patients experienced a >50% seizure reduction in the
CBZ–VPA group. Similar efﬁcacy data were reported for this
combination by other groups. Dean and Penry found that 54 of 100
carbamazepine-unresponsive patients with partial epilepsy had a
greater than 50% seizure reduction upon addition of valproate.5
Fifteen patients became seizure free.Walker and Koon performed a
study in which patients with complex partial seizures ﬁrst all
received VPA monotherapy.6 Patients who did not respond
sufﬁciently to this were given CBZ monotherapy and when they
again insufﬁciently responded they were given the combination of
VPA and CBZ. Of the 17 patients not responding to either CBZ or
VPA monotherapy, 12 beneﬁted from their combination, with 6
becoming seizure free.
There has only been one report about the effectiveness of the
combination of primidone and carbamazepine in epilepsy
patients.7 This was a report on a group of 31 patients who failed
to respond to monotherapy with CBZ at the maximum tolerated
dose. The patients were allocated to add-on treatment with VPA
(15 patients) or PRM (16 patients). The results were better for the
latter group: 10 patients experienced a greater than 50% seizure
reduction, whereas this was the case for only 4 of the patients in
the CBZ/VPA group. Tolerability did not differ between the two
groups.
We found that CBZ serum levels were lower in combination
therapy than in monotherapy. Similarly, Rambeck found that the
mean serum concentration of CBZ is lower when the drug is given
in combination with primidone and valproate than when CBZ isgiven alone, whereas the mean concentration of CBZ-epoxide is
increased especially by valproate.8
Our results indicated no signiﬁcant differences were found
concerning tolerability. In the animal experiments performed by
Bourgeois and co-workers, the efﬁcacy of the CBZ/VPA and CBZ/
PRM combinations were additive.9 The toxicity of the CBZ/PRM
combinationwas found to be additive, while infra-additive toxicity
was found for the CBZ/VPA combination. Infra-additive toxicity
may allow for higher dosages to be used, resulting in better
effectiveness.10 When we look at mechanisms of action of the
respective drugs, it is unclear why one of these combinations
should perform better than the other, as VPA and PRM seem to
mediate their effects through similar actions, i.e. through actions
on the GABAergic system and blockade of sodium channels.
There may be some criticism of the design of our study. First
of all, PRM was chosen of phenobarbital despite the fact that
primidone may be associated with more adverse effects during
the ﬁrst months of treatment.11 However, the percentage of
patients failing on PRM due to adverse effects was limited in our
study, and the efﬁcacy of PRM and phenobarbital may be
expected to be similar. Secondly, the average dosages used for
the add-on treatment were in the low range of dosages used in
clinical practice. It is possible that more patients would have
experienced a greater than 50% seizure reduction and more
patients would have become seizure free, when VPA and PRM
would have been titrated to higher dosages. However, it is likely
that more patients would have withdrawn from the study due to
adverse effects, when higher dosages had been used. The reason
for the careful titration schedule was the hypothesis that low
dosages of two treatments perform better than high dosages of a
single drug.12 It should also be pointed out that the effect of a
drug, whether in monotherapy or in combination therapy, is
already apparent at low dosages in most patients.13 A third point
of criticism may be the relatively short maintenance period of 3
months used in our study. Shorvon has stated that a drug should
be assessed at a therapeutic dose during a period three to ﬁve
times the previous interval between seizures.14 In placebo-
controlled add-on trials, patients with at least four seizures per
month are enrolled and this type of study usually has a 8–12
week maintenance period.15 With the relatively high baseline
seizure frequencies in our study, we feel that the length of the
maintenance period is justiﬁable.
The results of this trial suggest that for patients unresponsive
to carbamazepine, adding valproate is preferable to adding
primidone. Because of restricted health care resources, one may
be justiﬁed to try phenobarbital before trying valproate.
Valproate is still considerably less expensive than the new
antiepileptic drugs.
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